Haleon plc's stock activities have seen quite a significant change with a number of large investment firms buying or selling their shares. Institutions such as
Banco Santander S.A., Sei Investments Co., and Bleakley Financial Group adjusted their holdings with variations such as increase and decrease of stakes. Meanwhile,
GlaxoSmithKline (GSK) divested its remaining shares in Haleon, raising almost £1 billion.
Pfizer is also following suit, announced plans to cut its stake in Haleon from 32% to 24%, reducing Haleon's ownership in Sensodyne. Other companies including
Allspring Global Investments, Norden Group LLC, Russell Investments Group Ltd, and First Eagle Investment Management LLC also increased their stake. Despite
Deutsche Bank lowering their target for Haleon shares due to forecast revisions,
Haleon's stocks reached a new 12 month high at $9.00. The stock also saw a 5% surge after strong FY results led to a share buyback scheme. Short interest has increased by 6.6%.
Dr Reddy's Labs planned acquisition of Haleon's nicotine replacement business could see future stocks gains. There are plans for significant divestment and share buybacks, indicating potential shifts in the stock's future performance.
Haleon Stocks News Analytics from Thu, 05 Oct 2023 07:00:00 GMT to Sun, 21 Jul 2024 19:05:03 GMT -
Rating 7
- Innovation 3
- Information 8
- Rumor -6
